TY  - JOUR
AU  - Jiménez-Ubieto, Ana
AU  - Grande, Carlos
AU  - Caballero, Dolores
AU  - Yáñez, Lucrecia
AU  - Novelli, Silvana
AU  - Hernández, Miguel T
AU  - Manzanares, María
AU  - Arranz, Reyes
AU  - Ferreiro, José Javier
AU  - Bobillo, Sabela
AU  - Mercadal, Santiago
AU  - Galego, Andrea
AU  - Jiménez, Javier López
AU  - Moraleda, José María
AU  - Vallejo, Carlos
AU  - Albo, Carmen
AU  - Pérez, Elena
AU  - Marrero, Carmen
AU  - Magnano, Laura
AU  - Palomera, Luis
AU  - Jarque, Isidro
AU  - Coria, Erika
AU  - Rodriguez, Antonia
AU  - Martín, Alejandro
AU  - López-Guillermo, Armando
AU  - Salar, Antonio
AU  - Lahuerta, Juan José
AU  - GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative study group
PY  - 2017
DO  - 10.1002/cam4.1217
UR  - https://hdl.handle.net/10668/25019
T2  - Cancer medicine
AB  - Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two...
LA  - en
KW  - Autologous Stem Cell Trasplantation
KW  - CR 30
KW  - Follicular Lymphoma
KW  - PFS 24
KW  - Rituximab
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - Databases, Factual
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Endpoint Determination
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - Kaplan-Meier Estimate
KW  - Lymphoma, Follicular
KW  - Male
KW  - Middle Aged
KW  - Proportional Hazards Models
KW  - Registries
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Spain
KW  - Stem Cell Transplantation
KW  - Time Factors
KW  - Transplantation, Autologous
KW  - Treatment Outcome
KW  - Young Adult
TI  - Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.
TY  - research article
VL  - 6
ER  -